iCasp9M28z T cells

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameiCasp9M28z T cells
Drug Alias Nameanti-mesothelin CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center)anti-mesothelin iCasp9M28z CAR-transduced autologous T lymphocytesanti-mesothelin CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed cell death protein 1 blockersMesothelin modulators
TargetsMesothelinProgrammed cell death protein 1
Therapy Area/IndicationsLung NeoplasmsBreast NeoplasmsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics IncMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsBreast NeoplasmsMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A